Lacrimal Devices Market Size & Share 2025 - 2034

Lacrimal Devices Market Size

The global lacrimal devices market was valued at USD 160.2 million in 2024 and is expected to exhibit growth at a CAGR of 4.2% from 2025 to 2034. Due to increasing technological advancements in healthcare systems and rising cases of eye illnesses, the market is witnessing remarkable growth.

Surging cases of dry eye syndrome, often linked to overuse of digital screens, environmental pollution, and global aging also add to the growth of the market. Modern lacrimal devices, such as punctal plugs and stents which provide effective relief, are in great demand which in turn is propelling the market growth positively.
 

Furthermore, emerging nations have been experiencing better healthcare as well as awareness towards eye care, thus creating wider scope of the lacrimal device market. Providing better patient and procedural outcomes, new innovations including smart diagnostic tools and minimally invasive surgical instruments are also fostering the market growth. Moreover, government initiatives and policies focusing on research development in ophthalmic care and eyecare also aids in the growth of lacrimal devices market. 
 

Strong focus on patient-centered approaches from lacrimal device manufacturers fuels the market growth positively. Growing emphasis on personalized medicine makes the devices safer by improving biocompatibility, further supporting the trend. Besides, faster development of product and methodology owing to collaboration among healthcare providers and other industry & research stakeholders contributes to market expansion.
 

Lacrimal devices are medical instruments designed to diagnose, treat, and manage disorders of the tear drainage system, including conditions tear duct obstruction, such as dry eye syndrome, and excessive tearing. These instruments include punctal plugs, stents, syringes, and probes, that help in restoring normal tear function and maintain overall eye health.
 

Lacrimal Devices Market Trends

• The increasing adoption of lacrimal devices is anticipated in the following years. Conditions such as dry eye disease and the infection of dacryocystitis have remained prevalent over the last few years in both developed and developing economies. Additionally, it is estimated that approximately 6% to 20% of newborns experience symptoms related to nasolacrimal duct obstruction (NLDO). A significant proportion of these cases resolve on their own, with around 70% of symptomatic infants improving within three months and over 90% showing resolution within one year.
   
• Some studies show up to 20% of healthy newborns may be high risk for defective lacrimal drainage for the first year of life. This has led to an increasing demand in the product which has fueled the rise within the lacrimal device sector.
   
• Lacrimal disorders affect all age groups including the very young and the elderly. Some congenital disorders arise at birth while others develop around the age of forty. This suggests that the adult population will create a sustained demand to drive growth in the lacrimal device market globally.
   
• Along with this, Dry eye disease (DED) continues to remain one of the major concerns to the public health of an individual which is at the same time worsening the overall health of the U.S.
   
• The upsurge in DED cases not only in older populations but also in middle-aged people will serve as a catalyst to stimulate the increase of market.
   

Impact of Tariff on the Market

By imposing tariffs, the import of medical devices has become more complex and costly. Additionally, the expenses in sourcing raw materials, parts, equipment, and the finished product, tariffs can greatly affect the market on lacrimal devices by making this more expensive. For instance, the devices used for the treatment of tear drainage disorders are extremely sophisticated. They incorporate advanced technologies as well as specialized materials that are not available locally. Thus, these manufacturers are highly reliant on global supply chains which makes them extremely susceptible to trade barriers such as tariffs.
 

When tariffs are imposed on medical imports such as medical grade polymers, surgical instruments, or electronic lenses used in precision devices, it drives up costs across the entire production chain. Hence the cost of almost the entire production chain increases. This raises the price of lacrimal implants or drainage systems for both patients and providers.
 

Tariffs can significantly reduce demand for lacrimal devices in price-sensitive regions by making them unaffordable. Lack of order, or erratic tariff systems, makes international investment unfavorable. It limits mid and small sized traders the most. Closed borders lead to expensive markets, disturbed supply chains, restricted medical technology access, and aid open regions become more favorable for investment and production. Even though tariffs might stimulate economic growth in domestic manufacturing over a long time period, their short run impact is adverse for the growth of the market considering the increase in costs along with the minimal growth.
 

Lacrimal Devices Market Analysis

Based on product, the market is segmented into stents, intubation sets, punctal plugs, tubes, cannula and spatula, dilator, and other products. The stents segment is expected to expand at a CAGR of 4.6%, reaching over USD 67.9 million by 2034. Also, the global market was valued at USD 160.2 million in 2024.
 

• The segment's development is fostered by the rising prevalence of disorders of the lacrimal system such as nasolacrimal duct obstruction (NLDO) in pediatric and geriatric populations. These conditions regularly entail surgical intervention, such as stenting, due to excessive epiphora or recurrent infections. 
   
• Non-invasive procedures along with improvements in lacrimal stent technologies has increased the market demand for efficient, long-lasting, non cumbersome solutions. 
   
• The increasing choice of stents by ophthalmologists due to the uncomplicated design, ease of insertion, high postoperative patient satisfaction, and overall surgical success for NLDO and related procedures adds to the intrigue and complexity. Self retaining and bioresorbable stents are examples of innovative designs which decrease the burden of secondary invasive procedures required to extract protective stents. 
   
• Evaluating other factors which contribute to stent-bound tear duct obstructions, rising prevalence of diabetes and other autoimmune disorders does confirm the increasing demand as these conditions do predispose patients to lacrimal gland and tear duct obstructions.
   

Based on application, the lacrimal devices market is classified into dry eye, glaucoma, drainage obstruction, epiphora, lacrimal gland inflammation, and other application. The dry eye segment held 40.1% share of the market in 2024, driven by several key factors.
 

• The dry eye syndrome condition due to the aging population and lifestyle modifications like environmental pollution or prolonged screen time raises the need for effective treatments. The technological progress on lacrimal instruments like punctal plugs and new tear drainage management systems has improved patient outcomes which has increased usage.
   
• The increasing understanding of patients and providers regarding the treatment and diagnosis of dry eye conditions is also propelling market growth. Furthermore, the increasing burden of chronic conditions such as diabetes and autoimmune diseases which lead to secondary complications of dry eye are also driving the need for specific lacrimal interventions. 
   
• Broader availability of sophisticated dry eye diagnostic instruments are propelling the segment's growth as they improve accuracy in determining dry eye causes and treatment.
   

Based on material, the lacrimal devices market is segmented into silicone, stainless steel, and other materials. The silicone segment was valued at USD 73.2 million in 2024 and is expected to grow at a 4.7% CAGR between 2025 and 2034.
 

• The growing incidence of dry eye syndrome is being caused by changing lifestyles, population aging, increase in screen time and pollution. This has prompted advancements in treatment, including improved punctal plugs and tear drainage devices, leading to better patient outcomes and higher adoption rates. 
   
• The increasing emphasis on primary prevention of dry eye syndrome among patients and healthcare providers is also contributing to market expansion. In addition, the widening scope of chronic illnesses such as diabetes and autoimmune disorders which leads to secondary dry eye syndrome has exerted greater demand for specific lacrimal intervened devices.   
   
• These factors, combined with the growing need for accurate and timely diagnosis of dry eye causes and corresponding treatments, are expected to drive segment growth over the forecast period.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the lacrimal devices market is segmented into hospitals, ophthalmic clincs, diagnostic centers, and other end users. The hospitals segment dominated the market with a revenue share of 46.5% in 2024 and is anticipated to reach USD 112.4 million by 2034.
 

• The abundance of skilled doctors and specialized equipment have made healthcare centers the focal point for the management, diagnosis, and treatment of disorders of the lacrimal system. As more and more cases of dry eye syndrome, tear duct blockage, and epiphora are reported, the demand for such services is on the rise along with the need for more treatment facilities in hospitals.  
   
• These patients prefer such healthcare institutions because complicated case surgeries of DCR (endoscopic dacryocystorhinostomy) and lacrimal duct reconstruction are also done at hospitals.    
   
• Moreover, innovations in surgical techniques and imaging technologies have significantly enhanced hospitals ability to deliver effective and precise treatment.
   

In North America region, U.S. lacrimal devices market was valued at USD 53.5 million in 2024 and is projected to grow substantially in the coming years.
 

• An increase in the prevalence of certain lacrimal conditions such as dry eye syndrome, tear duct obstructions, and epiphora greatly escalates the demand for innovative methods in diagnosis and treatment. In the U.S., the older population plays a large part as they are more prone to systemic disorders such as arthritis and diabetes due to wear and tear aging changes, as well as rheumatism, and aging could lead to chronic diseases and dysfunctions of the lacrimal system. 
   
• Industry restructuring and innovation in the U.S. has led to an increase in demand for lacrimal devices including stents, punctal plugs as well as stenting-surgery-auxiliary procedures, and the placement of new stents which are more efficient and comfortable for the patients is contributing to the overall market growth.
   

In the Europe lacrimal devices market, the UK is projected to grow remarkably in the coming years.
 

• The market for the UK lacrimal devices is growing with regard to demographic factors, technology, and healthcare system. Over two million baby boomers above 65 years of age living in the UK are more prone to suffer from lacrimal system disorders like dry eye syndrome, an epiphora, and tear duct obstruction. The increasing prevalence of diabetes and autoimmune disorders further driving demand.
   
• The wide availability of educative resources along with enhanced eye health imaging technologies helps with the early diagnosis and treatment of eye diseases is further boosting the demand.
   
• NHS is UK’s largest single payer of health services, which enables wide accessibility of lacrimal treatments. The government initiatives target improving general eye care and covering certain lacrimal procedures enhances the growth of the market.
   

China holds a dominant position in the Asia Pacific lacrimal devices market.
 

• Combining urban growth, technological exposure, and an increasing aging population stricken with conditions like dry eye syndrome and tear duct obstructions escalates the need for lacrimal devices. Furthermore, increased knowledge pertaining to general eye care along with expanding diagnostic and therapeutic options of lacrimal devices is assisting in curing epiphora which aids in fulfilling the demand gap.
   
• Lucrative governmental policies directed toward eye care advancement coupled with the well built infrastructure in china facilitates access to lacrimal devices. Moreover, the increasing funding towards hospitals and specialized clinics is also improving access to these devices in remote areas.
   
• Cumulatively, these factors alongside generous reimbursement policies pertaining to ocular care services strengthen patient motivation for seeking medical attention towards lacrimal issues, thus propelling market demand.
   

Brazil holds a dominant position in the Latin America lacrimal devices market.
 

• There is a high and increasing prevalence of ocular disorders like dry eye syndrome and nasolacrimal duct obstruction due to the large and geriatric population base in the country. Greater spending by the government on public healthcare, along with the improving healthcare infrastructure in Brazil, has increased the availability of specialized ophthalmic care.
   
• There is also heightened awareness regarding the need for prompt intervention in diagnosing and treating ocular ailments, thus increasing the demand for sophisticated lacrimal devices. The availability of ophthalmic surgeons, public and private funding for the surgical procedures also aids in the market.
   
• Furthermore, steady supply is facilitated by local production efforts coupled with supportive policies on the importation of vital medical devices. All these factors combined allow Brazil to be one of the primary investment and expansion markets for internal and external suppliers in the region.
   

Lacrimal Devices Market Share

The market features key players like Aurolab, B. Braun, Bess Medical, Braintree, and others. The top 3 players accounted for around 60% share in the market. Along with the industry leaders the market is undergoing technological and materials innovations. New inventions, such as drug-eluting stents, implementation of less invasive surgical procedures, and the use of biocompatible implants are increasingly improving the patients results and recovery periods. Greater understanding and awareness of ophthalmic issues along with the surging aged population are augmenting the demand across markets.
 

The Asia-Pacific and Latin America regions are expected to experience strong growth due to developments in healthcare systems and increased availability of eye care services. Companies are also strategically pursuing collaborations or mergers to enhance their geographic presence and product offerings which alters the competitive environment. In addition, outpatient focused regulatory approvals for new devices are creating streamlined treatment pathways while lowering expenses. From a market perspective, these changes point towards overcoming cost-related hurdles while expanding in the lacrimal devices segment which has previously been considered more sophisticated.
 

Lacrimal Devices Market Companies

Prominent players operating in the lacrimal devices industry include:

• Aurolab
• B. Braun
• Bess Medical
• Braintree
• BVI
• FCI
• GWSG
• Innovia Medical
• JEDMED
• Kaneka Medical Products
• Medennium
• OASIS
• Rumex
• Surtex Instruments
• Walsh Medical Devices
   
• FCI Ophthalmic: The company’s reputation stems from the wide range of lacrimal stents and intubation sets offered. FCI Ophthalmic aspires to change the industry by focusing on quality innovation in ophthalmic surgical devices. The company’s broad range of products effectively solves patients’ issues and enhances the capabilities of healthcare practitioners dealing with different lacrimal system disorders.
   
• Kaneka Corporation: Kaneka Corporation has an expertise in biocompatible polymer lacrimal devices due to their advanced polymer technology. With their relentless focus in R&D, they are able to develop products that are comfortable for the patient and are clinically effective in treating lacrimal duct obstruction.
   

Lacrimal Devices Industry News:

• In January 2022, Kaneka Medical America LLC, the manufacturer of lacrimal devices, announced plans to set up a new facility in Northern Japan. This new plant will be located in Tohbu Industrial Park, Tomakoai, Hokkaido and will also be involved in the manufacturing of lacrimal devices. New site operations will start in May 2024.
   
• In November 2021, Innovia Medical announced the acquisition of Lacrimedics Inc. The acquisition aimed to enhance Innovia’s ophthalmic business and allow to provide ophthalmic customers with comprehensive occlusion therapy options, thereby strengthening market position.
   

The lacrimal devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Stents
• Intubation sets
• Punctal plugs
• Tubes
• Cannula and spatula
• Dilator
• Other products

Market, By Application

• Dry eye
• Epiphora
• Glaucoma
• Drainage obstruction
• Lacrimal gland inflammation
• Other applications

Market, By Material

• Silicone
• Stainless steel
• Other materials

Market, By End Use

• Hospitals
• Ophthalmic clinics
• Diagnostic centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE